Top companies

BPCL - 296.4 (0.9%) RELIANCE - 1349.6 (-0.74%) COALINDIA - 460.2 (0.33%) SBIN - 950.9 (0%) ASIANPAINT - 2598.8 (0.01%) ICICIBANK - 1242.8 (0.44%) ONGC - 295.85 (-0.82%) INDUSINDBK - 899.95 (0.31%) AXISBANK - 1253.3 (0.28%) ITC - 308.05 (0.16%) HEROMOTOCO - 4969.5 (0.03%) KOTAKBANK - 380.85 (-0.61%) TITAN - 4083.1 (-0.57%) TATASTEEL - 208.58 (0.76%) MARUTI - 13010 (0.05%) HINDUNILVR - 2179 (-1.37%) HDFCBANK - 759.15 (-0.05%) WIPRO - 199.74 (1.33%) BAJAJFINSV - 1752.2 (-1.12%) BHARTIARTL - 1885.3 (-1.03%) TCS - 2327.2 (-0.01%) BAJFINANCE - 907.65 (-1.67%)
TRENDING #Asian Paints Limited711 #ITC Limited613 #Axis Bank Limited533 #HDFC Bank Limited283

Short Call | Grappling with gap downs; Dr Reddy's, Siemens India in focus

23 Dec , 2024   By : Debdeep Gupta


Short Call | Grappling with gap downs; Dr Reddy's, Siemens India in focus

If you’ve been around the markets long enough, you’ve probably weathered five percent, ten percent, or even 40 percent corrections. But how often do you see the Nifty 50 open by nosediving one percent?


According to a quick crunch by Samco Securities, it’s rare, only 107 instances of a gap-down opening exceeding one percent have been recorded since 2000. When you look at the pandemic era, since April 2020, there have been 40 instances.


Here's why this is important: history shows that most of these dips have been followed by a sweet recovery. Over the next two months, the Nifty has bounced back 33 out of 40 times, posting an average gain of 5.36 percent.


Does this mean it’s time to celebrate? Not quite, since past performance isn’t indicative of future performance, we all know this. But why not use this to find a silver lining in the cloudy skies!


Dr Reddy's Labs (Rs 1,345.3, 1.5%)


Top gainer on the Nifty 50, gained 9% in three consecutive sessions.


Bull Case: Recent underperformance prices in concerns of high contribution of Revlimid. Capex has more than doubled in FY25 so far, aiming to improve operational capabilities and ramp-up of biosimilars, peptides, and other portfolios which is expeced to aid future growth.


Bear Case: Even though the management sees Revlimid as a significant opportunity through FY25 and FY26, increased competition after patent expiry in early 2026 may signifcantly weigh on earnings growth. High base of the previous year is likely to keep growth muted through the current fiscal.


Siemens India (Rs 6,885, -9.8%)


Shares took a tumble following weak management commentary, especially on the private capex front.


Bull Case: Private capex is happening in semiconductor, EV, battery, solar, and should continue to pick up. Government capex picking up in H2FY25 will also boost private capex. Nuvama expects the firm to significantly scale-up in new areas such as digital and factories & building technologies, which will boost growth and operating margin

given the high growth potential and scope for value addition.


Bear Case: A greater-than-anticipated slowdown in key infra verticals—including T&D, transportation and hydrocarbon—could impact Siemens India’s overall business growth.


0 Comment


LEAVE A COMMENT


Growmudra © 2026 all right reserved

Partner With Us